|
IVX last 17.00$ Ich glaube, daß unser generic game erst einmal für eine Weile vorbei sein wird. Die diesjährige performance vieler generics mit mehreren 100% läßt rein handelstechnisch nicht mehr viel Luft nach oben. Das Risiko nach unten ist meineserachtens bedeutend höher. @dosto zu Medical Equipment & Supplies/Generics und OREX/BRL Du hast da die 2$ von OREX und die 70$ von BRL verglichen. Das ist für mich keine Frage der Liga, sondern eine Frage des Chance/Risikoverhältnis. Wilmington, Delaware, Nov. 6 (Bloomberg) -- Merck & Co., the No. 3 drugmaker, asked a judge to affirm its patent for the anti- osteoporosis medicine Fosamax and to prevent rivals Teva Pharmaceuticals Industries Ltd. and Zenith Goldline Pharmaceuticals Inc. from marketing a generic version. Lawyers for Israel`s Teva and Zenith Goldline, a unit of Miami-based Ivax Corp., said Merck`s 1986 patent is invalid because the compound was invented earlier, as the non-jury trial before U.S. District Judge Joseph Farnan Jr. began in Delaware. Teva ranks No. 1 in sales among generic drugmakers. Merck lawyers countered that the drug in Fosamax isn`t the same as the earlier invention, patented in 1983, and that Teva and Zenith Goldline have infringed the Merck patent by asking the U.S. Food and Drug Administration for permission to sell generic Fosamax. ``Twenty million people in the U.S. have osteoporosis,`` said Merck`s lawyer, John Lynch, who wants Farnan to rule that Teva and Zenith Goldline can`t make generic Fosamax until Merck`s patent expires in 2007. ``It`s the first treatment that has been effective.`` Analysts have estimated that Fosamax, which strengthens bone tissue and helps prevent fractures in women after menopause, will have sales this year of about $1.5 billion. Shares of Merck, which reported $40.3 billion in fiscal 2000 sales, rose 6 cents to $65.44 today. American depositary receipts of Teva, which reported fiscal 2000 sales of $1.74 billion, fell 8 cents to $61.90. Shares of Ivax, with $793.4 million in fiscal 2000 sales, fell $2.15, or more than 11 percent, to $17 before trading was halted after a U.S. appeals court overturned federal approval for its generic version of the cancer drug Taxol in an unrelated case. `Different Compound` Lawyer James Galbraith, representing Teva and Zenith Goldline, said the companies` generic version contains ``a different compound, a different chemical entity`` than Merck`s drug and doesn`t infringe the patent. ``Merck is simply not entitled to protection for the drug because its existence was already known`` argued lawyer Stephen Roth, also representing Teva and Zenith Goldline. Whitehouse Station, New Jersey-based Merck sued Teva and Zenith Goldline early last year in separate lawsuits that were later consolidated. Merck`s 1986 U.S. patent was assigned to it by the Instituto Gentili SpA of Pisa, Italy, based on a pharmaceutical invention of chemists Sergio Rosina and Giorgio Staibano. The 1983 U.S. patent cited by Teva and Zenith Goldline was awarded to detergent and cosmetics maker Henkel KGaA of Duesseldorf, Germany, based on an invention by Helmut Blum and Karl-Heinz Worms. Merck ranked third in sales among pharmaceutical companies last year, trailing Pfizer and GlaxoSmithKline. |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | southbound (07.11.01 13:54:13) |
| Beitrag: | 54 von 125 (ID:4818916) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |